Publications by authors named "Steven L Abrams"

Claim this Profile
E
Emerging MEK inhibitors.
James A McCubrey, Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo

Expert Opin Emerg Drugs· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Raf inhibitors.
James A McCubrey, Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo

Expert Opin Emerg Drugs· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
James A McCubrey, Linda S Steelman, Richard A Franklin, Steven L Abrams, William H Chappell

Adv Enzyme Regul· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
James A McCubrey, Linda S Steelman, Steven L Abrams, John T Lee, Fumin Chang

Adv Enzyme Regul· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line.
John G Shelton, Linda S Steelman, Steven L Abrams, Edmund R White, Shaw M Akula

Cell Cycle· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines.
John G Shelton, Linda S Steelman, Steven L Abrams, Edmund R White, Shaw M Akula

Cell Cycle· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis